Trials / Completed
CompletedNCT04428411
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
The Impact of Difficult to Treat Sites on Biological Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 486 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel | As provided in real world practice |
Timeline
- Start date
- 2020-07-05
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
- First posted
- 2020-06-11
- Last updated
- 2021-10-25
- Results posted
- 2021-10-25
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04428411. Inclusion in this directory is not an endorsement.